Compass Pathways Posts 52-Week Data for Depression Trial

Compass Pathways reported durable 52-week results from Part C of its Phase 3 COMP005 study for its COMP360 psilocybin therapy, showing continued efficacy and tolerability for treatment-resistant depression.

Shares of Compass Pathways PLC (NASDAQ: CMPS) closed at $14.22, down 6.26% on the day following a previous close of $15.17, according to Finnhub market data.

"The data supports a dosing frequency of potentially two to three times annually," noted analysts at Stifel in a note following the trial update.

Clinical Endpoints and Dosing Intervals

In the 25mg arm of the study, patients achieved a mean 13-point reduction on the Montgomery-Åsberg Depression Rating Scale from baseline at the 52-week mark. This sustained response highlights the durability of the psychedelic-derived therapy over a full year of observation.

By comparison, existing treatments such as Johnson & Johnson's Spravato esketamine typically require once-weekly or bi-weekly administration schedules. The potential for dosing just two to three times annually could alter outpatient management protocols for severe depressive disorders.

Regulatory Timeline and Cash Position

The company remains on track to complete the final submission of its New Drug Application in the fourth quarter, with rolling regulatory review already underway. Leadership is positioning the enterprise for a potential commercial launch in the first half of 2027.

To fund operations through these regulatory milestones, Compass Pathways reported $433 million in cash reserves at the end of the second quarter. Management estimates this liquidity runway will support corporate operations through 2028.

What Is at Stake for Treatment-Resistant Depression

Treatment-resistant depression affects millions of patients who fail to respond to standard monoaminergic antidepressants such as selective serotonin reuptake inhibitors. The ongoing clinical evaluation of COMP360 represents a shift toward novel pharmacologic classes targeting neural plasticity, with commercial viability dependent on securing final FDA approval and favorable outpatient reimbursement schedules ahead of the 2027 launch window.